Liminal BioSciences Inc.
LMNL · NASDAQ
6/30/2023 | 3/31/2023 | 12/31/2022 | 9/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | -0.00 | 0.00 | -0.00 |
| FCF Yield | -1,105.79% | -2,380.25% | -1,686.71% | -2,381.64% |
| EV / EBITDA | 1.96 | 3.53 | 2.57 | 3.84 |
| Quality | ||||
| ROIC | -38.11% | -23.94% | -12.10% | 145.48% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.85 | 1.39 | 1.48 | -0.53 |
| Growth | ||||
| Revenue 3-Year CAGR | -36.36% | -39.49% | -50.55% | – |
| Free Cash Flow Growth | 24.78% | -64.68% | 46.33% | -72.43% |
| Safety | ||||
| Net Debt / EBITDA | 2.04 | 3.60 | 2.60 | 3.89 |
| Interest Coverage | 0.00 | -34.10 | -38.40 | -10.82 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 633.21 | 681.62 | 439.54 | 44,940.00 |